Angelman Syndrome
Comprehensive Guide to Angelman Syndrome: Diagnosis, Care, and Long-Term Management
What is Angelman Syndrome?
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder that primarily affects the nervous system. It was first described by Dr. Harry Angelman in 1965. AS is characterized by severe intellectual disability, absent or very limited speech, movement and balance problems (ataxia), seizures, and a uniquely happy and sociable demeanor with frequent laughter.
AS is caused by the loss of function of the UBE3A gene on chromosome 15 (region 15q11.2-q13). In most of the body, both copies of UBE3A (one from each parent) are active. However, in neurons of the brain, only the copy inherited from the mother is active — the father's copy is naturally silenced through a process called genomic imprinting. This means that if the mother's copy of UBE3A is lost or nonfunctional, there is no working UBE3A in the brain.
The estimated prevalence is approximately 1 in 15,000 live births.
There are four main genetic mechanisms that cause AS:
- Maternal deletion (~70% of cases) — a segment of the mother's chromosome 15 containing UBE3A is deleted. This is the most common cause and tends to produce the most severe symptoms, likely because neighboring genes (including GABA receptor genes) are also lost.
- UBE3A pathogenic variant (~11% of cases) — a mutation in the mother's copy of the UBE3A gene itself. Individuals with this mechanism may have somewhat less severe features.
- Paternal uniparental disomy (~2–5% of cases) — the child inherits two copies of chromosome 15 from the father and none from the mother.
- Imprinting defect (~3% of cases) — the mother's UBE3A gene is present but abnormally silenced.
In approximately 10% of individuals with clinical features of AS, no molecular abnormality can be identified with current testing.
Identifying the specific genetic mechanism is essential because it directly affects recurrence risk for future pregnancies and influences the clinical presentation.
---
What are the Characteristic Features of Angelman Syndrome?
AS affects multiple body systems. Not every individual will have all features, and severity varies — particularly between genetic subtypes. Developmental delays are first noted around age 6 months. Early symptoms may be present including early laughter or visual abnormalities.
The consensus clinical diagnostic criteria organize features into three categories:
Consistent features (present in virtually all individuals):
- Severe developmental delay and intellectual disability
- Severe speech impairment — most individuals are nonverbal or have only a few words; receptive language (understanding) is stronger than expressive language (speaking)
- Movement disorder — ataxia (unsteady, jerky gait), tremulousness of the limbs
- Unique behavioral profile — frequent laughter and smiling, apparent happy demeanor, excitability, hand-flapping movements, hyperactivity, short attention span, fascination with water
Frequently associated features:
- Microcephaly (small head size) — usually progressive, becoming apparent by age 2 years
- Seizures — occur in up to 80–90% of individuals, typically beginning between ages 1 and 3 years. The most common types are myoclonic and atypical absence seizures. Seizures are often difficult to control (pharmacoresistant). Fever-provoked seizures are characteristic. Nonconvulsive status epilepticus is a unique and underrecognized feature that can last hours to days and cause loss of developmental skills.
- Characteristic EEG abnormalities — runs of high-amplitude delta activity with intermittent spike-and-slow-wave discharges; rhythmic theta activity. These EEG patterns can help support the diagnosis even before genetic testing.
Less common features:
- Flat back of the head (flat occiput)
- Tongue protrusion and protruding jaw (prognathia)
- Wide mouth with widely spaced teeth
- Drooling
- Excessive chewing/mouthing behaviors
- Light skin and hair pigmentation (especially in those with the deletion subtype, due to co-deletion of the OCA2 gene)
- Increased sensitivity to heat
- Uplifted, flexed arms during walking
Facial features:
- Wide, smiling mouth
- Prominent chin
- Deep-set eyes
- Subtle dysmorphic features that may become more apparent with age — adults may develop coarser facial features
Sleep disturbances (70–80%):
- Difficulty falling asleep and staying asleep
- Frequent nocturnal awakenings
- Decreased need for sleep — some children sleep fewer than 4 hours per night
- Sleep problems tend to improve with age but remain significant for many adults
- Severely reduced melatonin levels have been documented in many individuals
Gastrointestinal:
- Constipation (up to 84%) — one of the most common and persistent features across all ages
- Gastroesophageal reflux (53–64%)
- Feeding difficulties, especially in infancy (poor suck, difficulty with breastfeeding)
- Swallowing difficulties
- Food-seeking behaviors and obesity risk in older children and adults
Musculoskeletal:
- Scoliosis (approximately 30% of adults)
- Subluxed or pronated ankles
- Tight Achilles tendons
- Low bone density/osteoporosis (approximately 20% of adults)
Eyes:
- Strabismus (crossed eyes)
-Cerebral vision impairment
Behavioral changes with age:
- The excitable, happy demeanor tends to decrease with age
- Anxiety becomes increasingly common — affecting approximately 57% overall and up to 71% of adults ages 26–43
- Defiant behaviors tend to decrease with age
- Tremor and nonepileptic myoclonus may increase with age
Life expectancy appears to be nearly normal.
---
How is Angelman Syndrome Diagnosed?
Diagnosis is based on a combination of clinical features and molecular genetic testing.
Clinical suspicion should be raised when a child presents with:
- Developmental delay noticeable by 6–12 months
- Absent or very limited speech
- Movement disorder (ataxia, tremulousness)
- Characteristic behavioral features (frequent laughter, excitability, hand-flapping)
- Seizures with characteristic EEG abnormalities
- Progressive microcephaly
- Early laughter
Genetic testing algorithm:
1. DNA methylation analysis (first-tier test) — analyzes parent-specific methylation patterns at the SNRPN locus in the 15q11.2-q13 region. This test detects approximately 80% of individuals with AS, including those with a deletion, uniparental disomy, or imprinting defect.
2. If methylation is abnormal, additional testing determines the specific molecular subtype:
- Chromosomal microarray or FISH — to identify deletions
- DNA polymorphism analysis — to distinguish uniparental disomy from imprinting defects
- Imprinting center analysis — to identify imprinting center deletions
3. If methylation is normal but clinical suspicion remains high, UBE3A sequence analysis should be performed — this detects pathogenic variants in an additional approximately 11% of individuals.
4. Combined, molecular genetic testing identifies alterations in approximately 90% of individuals with AS. The remaining 10% with classic features have the disorder due to an as-yet unidentified genetic mechanism.
A clinical geneticist is essential for applying the diagnostic criteria, coordinating the appropriate testing algorithm, and providing accurate genetic counseling.
---
What Evaluations are Recommended After Diagnosis?
Once AS is diagnosed, the following evaluations are recommended if not already completed:
- Neurology evaluation — to characterize seizure type(s), and establish an anti-seizure medication plan
- Developmental assessment — to establish a cognitive and motor baseline and determine the types of services needed
- Speech-language pathology evaluation — to assess communication abilities and determine the most appropriate augmentative and alternative communication (AAC) strategy
- Ophthalmology evaluation — to assess for strabismus (in the first year of life if present; at age 2 years for all individuals)
- Gastrointestinal evaluation — to assess for constipation, reflux, feeding difficulties, and swallowing safety
- Orthopedic evaluation — to assess for scoliosis, ankle instability, and tight Achilles tendons
- Sleep assessment — to characterize sleep disturbances and guide treatment
- Behavioral assessment — to identify hyperactivity, anxiety, and any self-injurious behaviors
- Genetic counseling — to inform the family about the specific molecular mechanism, recurrence risk, and implications for family planning
---
How is Angelman Syndrome Managed?
There is no cure for AS, but comprehensive management significantly improves quality of life. Care is individualized and typically involves multiple specialists.
Seizure management:
- Anti-seizure medications are the cornerstone of epilepsy treatment in AS
- Levetiracetam and clobazam are the most commonly used first-line medications
- Other medications with documented utility include valproate, topiramate, lamotrigine, ethosuximide, and clonazepam
- Cannabidiol (Epidiolex) and brivaracetam are newer options being used for refractory seizures
- Carbohydrate-restricted diets (ketogenic diet, low glycemic index treatment) may be considered for drug-resistant epilepsy
- Vagus nerve stimulation (VNS) may be considered for refractory cases
- Important: Nonconvulsive status epilepticus should be considered when there is unexplained loss of skills, diminished awareness, or prolonged altered behavior
Important precautions regarding seizure management:
- Avoid overtreatment with sedating medications to reduce hyperexcitable and hypermotoric behavior — these behaviors are part of the AS phenotype and do not always represent seizures
- Avoid overtreatment with anti-seizure medications when movement abnormalities (tremor, ataxia) are mistaken for seizures
- EEG abnormalities may persist even when seizures are well controlled — do not escalate treatment based on EEG alone if seizures are controlled clinically
Sleep management:
- Behavioral interventions should be first-line — psychoeducation, consistent bedtime routines, and sleep hygiene have shown positive and persistent effects
- Melatonin is the most commonly used medication for sleep initiation
- Clonidine and trazodone are also commonly used with favorable tolerability
- Mirtazapine may be considered for refractory sleep disturbances, particularly nocturnal awakenings, though weight gain is a common side effect
- Sleep problems tend to improve with age
Communication:
- Augmentative and alternative communication (AAC) is essential for most individuals with AS
- Options include picture cards, communication boards, sign language, and electronic voice-generating devices
- AAC should be introduced early and does not hinder verbal development
- Ongoing speech-language therapy with emphasis on nonverbal methods
Development and education:
- Physical therapy to improve gross motor skills, balance, and gait
- Occupational therapy to improve fine motor skills and self-help skills
- Early intervention services beginning in infancy
- Individualized education plans (IEPs) with flexibility in school settings
- Behavioral modification strategies for disruptive or self-injurious behaviors
Gastrointestinal management:
- Routine management of constipation with dietary fiber, stool softeners, and/or osmotic laxatives
- Treatment of gastroesophageal reflux with positioning, dietary modifications, and acid-suppressing medications as needed
- Monitoring for feeding difficulties and swallowing safety
- Evaluation of older children and adults for obesity associated with excessive appetite
Musculoskeletal management:
- Annual clinical examination for scoliosis — thoraco-lumbar jackets and/or surgical intervention as needed
- Bracing or surgery for subluxed or pronated ankles or tight Achilles tendons
- Monitoring for low bone density/osteoporosis in adults
Eyes:
- Ophthalmology examination in the first year if strabismus is present
- Routine ophthalmology exam at age 2 years with follow-up per ophthalmologist
Behavioral management:
- Structured environment with predictable routines
- Behavioral modification techniques for disruptive behaviors
- Monitoring for increasing anxiety with age — behavioral and/or pharmacologic interventions as needed
---
Recommended Ongoing Surveillance
At each clinical visit:
- Monitor for new seizures and/or changes in seizure pattern
- Assess developmental progress
- Evaluate behavior, including anxiety and self-injurious behaviors
- Assess mobility and motor skills
- Monitor gastrointestinal symptoms (constipation, reflux, feeding)
- Assess sleep quality
Annually:
- Clinical examination for scoliosis
- Ophthalmology follow-up (per ophthalmologist recommendations)
As indicated:
- Evaluation for obesity in older children and adults
- Bone density screening in adults
- EEG monitoring when seizure pattern changes or loss of skills is observed
---
Emerging Disease-Modifying Therapies
An exciting area of active research involves therapies aimed at reactivating the silenced paternal copy of UBE3A in the brain. Because individuals with AS have an intact but silenced paternal UBE3A gene, strategies to "turn on" this gene could potentially address the root cause of the disorder.
Antisense oligonucleotide (ASO) therapy is the most clinically advanced approach. ASOs are short pieces of synthetic DNA that can block the antisense transcript (UBE3A-ATS) that silences the paternal UBE3A gene. Three ASO candidates are currently in clinical development:
- Rugonersen (RO7248824) — completed a Phase 1 trial (TANGELO) in 61 children ages 1–12 years, showing an acceptable safety profile and signals of clinical improvement in core AS symptom domains
- ION582 and GTX-102/apazunersen are also in clinical development
Two of these candidates are advancing to pivotal Phase 3 trials.
Other approaches under investigation include gene replacement therapy, CRISPR-based gene editing, and small molecule therapies.
These advances highlight the importance of early diagnosis, as earlier treatment may provide greater benefit.
---
Genetic Counseling and Family Planning
Recurrence risk depends entirely on the specific genetic mechanism identified in the affected individual:
- Maternal deletion (~70% of cases): Recurrence risk is typically less than 1%, as most deletions are de novo. However, maternal germline mosaicism has been reported.
- Paternal uniparental disomy (~2–5%): Recurrence risk is typically less than 1% if both parents have normal chromosome analyses. However, if the father has a 15;15 Robertsonian translocation, recurrence risk approaches 100%.
- Imprinting defect with imprinting center deletion (~0.3%): If the mother carries the imprinting center deletion, recurrence risk is up to 50%. If not detected in maternal DNA, risk is less than 1%.
- Imprinting defect without imprinting center deletion (~2.5–3%): Recurrence risk is less than 1%.
- UBE3A pathogenic variant (~11%): If the mother carries the variant, recurrence risk is 50%. Approximately 30% of UBE3A variants are inherited from the mother. Even if the variant is not detected in maternal blood, prenatal testing should be offered due to the possibility of maternal germline mosaicism.
- No identifiable molecular abnormality (~10%): Recurrence risk is undetermined.
Once the genetic mechanism is identified, prenatal testing and preimplantation genetic testing are available for future pregnancies. Genetic counseling is recommended for all families, and members of the mother's extended family may also be at increased risk when an imprinting defect or UBE3A mutation is present.
---
Resources
Angelman Syndrome:
- Angelman Syndrome Foundation (ASF) — www.angelman.org
National organization providing family support, research funding, clinical resources, and community connections
- Foundation for Angelman Syndrome Therapeutics (FAST) — www.cureangelman.org
Nonprofit dedicated to funding research toward disease-modifying treatments for AS
- GeneReviews: Angelman Syndrome — www.ncbi.nlm.nih.gov/books/NBK1144
Expert-authored clinical summary including diagnosis, management, surveillance, and genetic counseling recommendations
- MedlinePlus: Angelman Syndrome — medlineplus.gov/genetics/condition/angelman-syndrome
National Library of Medicine resource with patient-friendly overviews of genetics, features, and inheritance
- NORD (National Organization for Rare Disorders) — rarediseases.org
Disease-specific information, patient assistance programs, and connections to clinical experts
- Genetic and Rare Diseases Information Center (GARD) — rarediseases.info.nih.gov
NIH-supported resource with detailed information and links to clinical trials
Epilepsy and Seizure Management:
- Epilepsy Foundation — www.epilepsy.com
Education, support, and resources for families of children with epilepsy
Sleep Support:
- American Academy of Sleep Medicine — www.aasm.org
Patient education resources and sleep center finder tool
Communication Support:
- American Speech-Language-Hearing Association (ASHA) — www.asha.org
Resources on augmentative and alternative communication (AAC) and finding a speech-language pathologist
Genetic Testing and Counseling:
- National Society of Genetic Counselors — www.findageneticcounselor.com
Directory to locate a board-certified genetic counselor
- ClinicalTrials.gov — www.clinicaltrials.gov
Search for active clinical trials related to Angelman syndrome, including ASO therapies and other disease-modifying treatments
General Support:
- Global Genes — www.globalgenes.org
Rare disease patient advocacy organization providing resources, community connections, and support programs
- The Arc — www.thearc.org
National organization advocating for and serving people with intellectual and developmental disabilities
